Journal
EUROPEAN JOURNAL OF PHARMACOLOGY
Volume 628, Issue 1-3, Pages 108-115Publisher
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ejphar.2009.11.045
Keywords
Memory and learning impairment; Dexamethasone; Amyloid precursor protein; Apoptosis; Alzheimer's disease
Categories
Funding
- Shiwu Technology Special Foundation [01803016]
- Nature Science Foundation of Anhui Province [00144414]
- Talents Exploitation Foundation of Anhui Province [2007z030]
- Department of Anhui Province Education [2005hbz18, KJ2009A81]
Ask authors/readers for more resources
Alzheimer's disease is a chronic neurodegenerative disorder marked by a progressive loss of memory and cognitive function. Stress level glucocorticoids are correlated with dementia progression in patients with Alzheimer's disease. In this study, twelve month old male mice were chronically treated for 21 days with stress-level dexamethasone (5 mg/kg). We investigated the pathological consequences of dexamethasone administration on learning and memory impairments, amyloid precursor protein processing and neuronal cell apoptosis in 12-month old male mice. Our results indicate that dexamethasone can induce learning and memory impairments, neuronal cell apoptosis, and mRNA levels of the amyloid precursor protein, beta-secretase and caspase-3 are selectively increased after dexamethasone administration. Immunohistochemistry demonstrated that amyloid precursor protein, caspase-3 and cytochrome c in the cortex and CAI, CA3 regions of the hippocampus are significantly increased in 12-month old male mice. Furthermore, dexamethasone treatment induced cortex and hippocampus neuron apoptosis as well as increasing the activity of caspase-9 and caspase-3. These findings suggest that high levels of glucocorticoids, found in Alzheimer's disease, are not merely a consequence of the disease process but rather play a central role in the development and progression of Alzheimer's disease. Stress management or pharmacological reduction of glucocorticoids warrant additional consideration of the regimen used in Alzheimer's disease therapies. (C) 2009 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available